Masimo Co. (NASDAQ:MASI) CEO Sells $3,505,339.07 in Stock

Masimo Co. (NASDAQ:MASI) CEO Joe E. Kiani sold 21,907 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $160.01, for a total transaction of $3,505,339.07. Following the sale, the chief executive officer now directly owns 159,838 shares in the company, valued at $25,575,678.38. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of MASI traded down $3.84 during mid-day trading on Friday, hitting $146.55. 221,005 shares of the company were exchanged, compared to its average volume of 390,304. Masimo Co. has a 1-year low of $98.23 and a 1-year high of $160.25. The company has a 50 day moving average of $152.92 and a 200-day moving average of $139.72. The stock has a market cap of $8.02 billion, a price-to-earnings ratio of 48.37, a price-to-earnings-growth ratio of 2.33 and a beta of 1.14.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $0.76 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.03. The company had revenue of $229.60 million during the quarter, compared to the consensus estimate of $222.46 million. Masimo had a net margin of 22.15% and a return on equity of 17.82%. Masimo’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.73 EPS. On average, equities research analysts expect that Masimo Co. will post 3.15 EPS for the current year.

Several equities research analysts have recently issued reports on the stock. Piper Jaffray Companies increased their target price on shares of Masimo from $148.00 to $160.00 in a research note on Friday, May 17th. Zacks Investment Research upgraded shares of Masimo from a “hold” rating to a “buy” rating and set a $153.00 price target for the company in a research report on Wednesday, May 8th. UBS Group upped their price target on shares of Masimo from $172.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. BTIG Research restated a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $158.00 price target (up previously from $155.00) on shares of Masimo in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $159.25.

A number of hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC raised its holdings in Masimo by 0.3% in the 1st quarter. MetLife Investment Advisors LLC now owns 29,816 shares of the medical equipment provider’s stock valued at $4,123,000 after acquiring an additional 90 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Masimo by 0.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 23,693 shares of the medical equipment provider’s stock valued at $3,276,000 after acquiring an additional 116 shares during the last quarter. Arizona State Retirement System increased its holdings in shares of Masimo by 0.4% during the 1st quarter. Arizona State Retirement System now owns 35,126 shares of the medical equipment provider’s stock worth $4,857,000 after buying an additional 132 shares during the last quarter. Bridge City Capital LLC increased its holdings in shares of Masimo by 0.5% during the 2nd quarter. Bridge City Capital LLC now owns 29,426 shares of the medical equipment provider’s stock worth $4,379,000 after buying an additional 144 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its holdings in shares of Masimo by 1.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 9,040 shares of the medical equipment provider’s stock worth $1,345,000 after buying an additional 150 shares during the last quarter. Institutional investors own 82.91% of the company’s stock.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: How Do Front-End Loads Impact an Investment?

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.